Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

The study found that rapid induction—administration of a single dose of 4-mg oral buprenorphine followed by a same-day SUBLOCADE injection—was well tolerated and led to higher retention at the second ...

Sublocade (buprenorphine) and Vivitrol (naltrexone) are prescription drugs used to treat opioid use disorder. Vivitrol is also prescribed for alcohol use disorder. Both drugs come as an injection ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability. 1 ...

Sublocade (buprenorphine) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat opioid use disorder in adults, as part of a complete treatment ...

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe. Publications highlight the importance of overcoming access barriers to ...

RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE TM (buprenorphine ...

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

This announcement contains inside information. RICHMOND, Virginia and SLOUGH, England, Dec. 1, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration ...